News | Radiation Therapy | October 21, 2022

Clinical outcome oral presentations on SMART Pancreas and MIRAGE prostate studies 

Clinical outcome oral presentations on SMART Pancreas and MIRAGE prostate studies    Varian, a Siemens Healthineers company, is highlighting its portfolio of intelligent, end-to-end imaging and cancer care technologies and services during the 2022 American Society for Radiation Oncology (ASTRO) annual meeting

October 21, 2022 — ViewRay, Inc. (NASDAQ: VRAY) today announced that the company's MRIdian MRI-Guided Radiation Therapy System will be featured at the 64th Annual Meeting of the American Society for Radiation Oncology (ASTRO), being held October 23-26, 2022, at the Henry B. González Convention Center in San Antonio, Texas. The meeting will feature numerous presentations and posters highlighting MRIdian's cutting-edge Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) technology, including oral presentations providing results of the multi-center SMART Pancreas study and MIRAGE, a Phase III randomized controlled prostate trial. In addition, initial clinical experience using MRIdian A3i will be highlighted during the conference. 

On Tuesday, October 25, 2022, at 3:00 p.m. CT, Dr. Parag Parikh from Henry Ford Health System will provide an oral presentation titled "Stereotactic MR-Guided On-Table Adaptive Therapy (SMART) for Patients with Borderline or Locally Advanced Pancreatic Cancer: Primary Endpoint Outcomes of a Prospective Phase II Multi-Center International Trial." The SMART study (NCT03621644) is a prospective clinical study exploring the clinical benefits of ablative MR-guided radiation therapy in the treatment of borderline resectable or inoperable locally advanced pancreatic cancer. 

On Wednesday, October 26, 2022, at 11:00 a.m. CT, Dr. Amar Kishan from UCLA will provide an oral presentation titled "Magnetic Resonance Imaging-Guided vs. Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer (MIRAGE): Primary Endpoint Analysis of a Phase III Randomized Trial". This clinical study compared MRIdian MRI-guided SBRT vs. CT-guided SBRT for localized prostate cancer. At ASCO GU 2022, Dr. Kishan reported the interim findings and analysis of the primary endpoint that signaled superiority of MRIdian MRI-guided SBRT compared to CT-guided SBRT. During this presentation, he will be presenting the final results of acute GU and GI toxicity. 

In addition, there will be dozens of scientific session presentations and posters highlighting the important role of MRIdian in cancer care treatment, including data supporting its clinical value in the treatment of cancers including pancreas, prostate, bladder, liver, kidney, and lung including ultra-central lung lesions, as well as oligometastatic disease. There will also be presentations focused on MRIdian's benefits in delivering reirradiation and on-table adaptive therapy. 

On Monday, October 24, 2022, at 4:00 p.m. CT, ViewRay will host an Industry Expert Theater titled "MRIdian A3i – Newest Innovation of MRgRT for Prostate, Pancreas, and Brain" featuring experts from Henry Ford Health System and Miami Cancer Institute sharing their initial clinical experience treating patients with MRIdian A3i. 

The new MRIdian A3i features enable clinicians to collaborate simultaneously and connect remotely during patient treatment. The new automated workflow steps and contouring tools are designed to minimize clinician time and increase patient throughput. MRIdian A3i also expands existing real-time tissue tracking and automated beam gating functionalities to include multiplanar, 3D tracking and gating in up to three planes. 

On Sunday night, October 23, 2022, at 6:30 p.m. CT, ViewRay will host an evening reception with special guest and cancer advocate Katie Couric, as part of ViewRay's previously announced national awareness campaign and partnership with Katie Couric Media to educate patients and clinicians about MRIdian SMART. Couric will moderate a discussion with ViewRay's CEO, Scott Drake, and radiation oncologists treating patients on MRIdian. 

ViewRay will also host customer presentations throughout the conference in the company's booth #3770, where customers will highlight their clinical experience treating patients on MRIdian. 

MRIdian provides radiation oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable organs-at-risk and healthy tissue and allows the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on implanted markers. By providing real-time continuous tracking of the target and organs-at-risk, MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins. This allows for delivery of the prescribed dose to the target, while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy. 

For more information: 
Find more ASTRO22 content here 

Related Content:  

Varian Receives Investigational Device Exemption (IDE) for Flash Technology Clinical Trial, FAST-02 

VIDEO: First FLASH Proton Therapy Trial Completed in Humans  

Related Content

News | PET Imaging

March 23, 2023 — Nuclidium announced that the Neuroendocrine Tumors Research Foundation (NETRF) has selected the company ...

Time March 24, 2023
News | Lung Imaging

March 22, 2023 — The Riverain Technologies ClearRead Bone Suppression solution is now available on the Siemens ...

Time March 22, 2023
News | X-Ray

March 20, 2023 — Researchers from UNSW Sydney have developed an algorithm which produces high-resolution modeled images ...

Time March 20, 2023
News | Artificial Intelligence

March 17, 2023 — A new paper published in the Journal of Medical Internet Research describes how generative models such ...

Time March 17, 2023
News | Quality Assurance (QA)

March 16, 2023 — RTsafe, a leading provider of quality assurance products and services in stereotactic radiosurgery ...

Time March 16, 2023
Feature | Magnetic Resonance Imaging (MRI) | By Brad Sutton

March 16, 2023, marks 50 years since Paul Lauterbur published his seminal Nature paper establishing zeugmatography — now ...

Time March 16, 2023
News | Lung Imaging

March 15, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR) ...

Time March 15, 2023
News | Radiation Oncology

March 14, 2023 — Elekta announced that is has signed a joint venture with China National Pharmaceutical Group Co., Ltd. ...

Time March 14, 2023
News | Digital Pathology

March 13, 2023 — Proscia, a leading provider of digital and computational pathology solutions, today announced that ...

Time March 13, 2023
Feature | Radiology Business | By Christine Book

With an increasing focus on personalizing the patient experience and enhancing communication between radiologists and ...

Time March 10, 2023
Subscribe Now